

Please reply to:

Senior Director, EC Registration
Authorised Representative (MDD)

Alcon

ALCON LABORATORIES (U.K.) LIMITED,
PENTAGON PARK, BOUNDARY WAY,
HEMEL HEMPSTEAD, HERTS,
ENGLAND HP2 7UD
TEL 01442 (Int +44 1442) 341234
FAX 01442 (Int +44 1442) 341200
<http://www.alconlabs.com/gb>

Direct Line:

Date: 14th February 2006

Dr D. Brasseur
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: Withdrawal of Opatanol (Olopatadine hydrochloride) 6 mg/ml nasal spray,
EMEA/H/C/407/X/04

Dear Dr Brasseur,

I would like to inform you that Alcon Laboratories (UK) Ltd has taken the decision to withdraw the application for Marketing Authorisation of Opatanol (Olopatadine hydrochloride) 6 mg/ml nasal spray, which was intended to be used for the treatment of the symptoms of season and perennial allergic rhinitis, at this point of time.

This withdrawal is based on the following reasons :

- Alcon's marketing strategy

It is confirmed that there are no ongoing clinical trials nor compassionate use programmes with Opatanol nasal in the EU.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,



Alcon Laboratories (U.K.) Limited (Registered in England No. 968373)
Registered Office: Pentagon Park, Boundary Way, Hemel Hempstead, Herts HP2 7UD

